Unilever Ventures had held a majority stake in smoothie brand Froosh since 2008, but has exited through an acquisition by Fazer for an undisclosed sum.

Nightstar has added a licence for a potential treatment of Stargardt disease to its portfolio.

Microbiosensor will use the funding to advance its handheld infection diagnosis tool through critical development and clinical testing.

The Public University of Navarre spinout will use the funds to prepare clinical trials of its biomarker-based asthma diagnosis device.

The Germany-based, Ammann and Staidson-backed inflammatory disease therapy developer has floated in an initial public offering in the US.

Existing backer Orange Digital Ventures and fellow corporate investor Stripe have participated in mobile bank Monzo's latest round.

Chromosol is commercialising optical amplifiers for semiconductors that transmit data via light pulses rather than as electrical signals.

The Unilever-backed augmented reality game developer has secured $5.8m to grow its presence in the UK and expand internationally.

The autoimmune drug developer has received $4.6m from Boehringer Ingelheim Venture Fund to take its series A round to $20.8m.

The targeted marketing software devloper has raised funding in a round co-led by corporate venturing unit Vorwerk Ventures.